Share This Article:

Recent Advances in the Management of Stage IV Colon Cancer

Abstract Full-Text HTML Download Download as PDF (Size:618KB) PP. 1104-1118
DOI: 10.4236/jct.2012.36145    4,925 Downloads   7,797 Views   Citations

ABSTRACT

Colon cancer is the second commonest cause of cancer-related death in Canadian men and women, with approximately one-third of patients dying from this disease. One quarter of patients present with metastases initially, and up to half of all colon cancer patients will develop stage IV disease over the course of their life. Despite ongoing advances in the evolution of newer cytotoxic drugs, targeted biological agents and improved metastasectomy techniques, the gain in overall survival in these patients is of low magnitude. This manuscript is a targeted review of the recent advances over the last decade in the management of advanced stage IV colon cancer as available in the published English literature. The two major arms of metastatic colon cancer management that include surgery and systemic chemotherapy and palliative measures as available are discussed. A multi-modality team-based approach involving medical oncologists, surgical oncologists, radiologists, and other health-care providers continues to be critical for ongoing success in the therapeutic management of these patients. Future studies of well-designed prospective, randomized-controlled clinical trials to develop and evaluate newer therapeutic strategies are recommended for continued and improved understanding for optimization of clinical management in advanced colon cancer.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

R. Kanthan, J. Senger, S. Ahmed and S. Kanthan, "Recent Advances in the Management of Stage IV Colon Cancer," Journal of Cancer Therapy, Vol. 3 No. 6, 2012, pp. 1104-1118. doi: 10.4236/jct.2012.36145.

References

[1] R. Kanthan, J. L. Senger and S. C. Kanthan, “Fecal Molecular Markers for Colorectal Cancer Screening,” Gastroenterology Research and Practice, 2012, Article ID: 184343.
[2] D. L. Bartlettt and E. Chu, “Can Metastatic Colorectal Cancer Be Cured?” Oncology, Vol. 26, No. 3, 2012, pp. 266-275.
[3] Y. N. Hsu, J. K. Lin, W. S. Chen, et al., “A New Classification Scheme For Recurrent or Metastatic Colon Cancer after Liver Metastasectomy,” Journal of the Chinese Medical Association, Vol. 74, No. 11, 2011, pp. 493-499. doi:10.1016/j.jcma.2011.09.004
[4] C. Verhoef, J. H. de Wilt, J. W. A. Burger, H. M. W. Verheul and M. Koopman, “Surgery of the Primary in Stage IV Colorectal Cancer with Unresectable Metastases,” European Journal of Cancer, Vol. 47, Suppl. 3, 2011, pp. S61-S66. doi:10.1016/S0959-8049(11)70148-4
[5] “What Are the Survival Rates for Colorectal Cancer?” 2012. http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-survival-rates
[6] R. Kanthan, J. L. Senger and S. C. Kanthan, “Molecular Events in Primary and Metastatic Colorectal Carcinoma: A Review,” Pathology Research International, 2012, Article ID: 597497.
[7] E. K. Abdalla, R. Adam, A. J. Bilchik, et al., “Improving Resectability of Hepatic Colorectal Metastases: Expert Consensus Statement,” Annals of Surgical Oncology, Vol. 13, No. 10, 2006, pp. 1271-1280. doi:10.1245/s10434-006-9045-5
[8] V. P. Khatri, N. J. Petrelli and Belghiti, “Extending the Frontiers of Surgical Therapy for Hepatic Colorectal Metastases: Is There a Limit?” Journal of Clinical Oncology, Vol. 23, No. 33, 2005, pp. 8490-8499. doi:10.1200/JCO.2004.00.6155
[9] I. S. Anwar, M. B. Peter, J. Dent and N. A. Scott, “Palliative Excisional Surgery for Primary Colorectal Cancer in Patients with Incurable Metastatic Disease. Is There a Survival Benefit?” Colorectal Disease, Vol. 14, No. 8, 2012, pp. 920-930. doi:10.1111/j.1463-1318.2011.02817.x
[10] K. B. Glimelius and N. Cavalli-Bjorkman, “Metastatic Colorectal Cancer: Current Treatment and Future Options for Improved Survival,” Scandinavian Journal of Gastroenterology, Vol. 47, No. 3, 2012, pp. 296-314. doi:10.3109/00365521.2012.640828
[11] T. S. K. Kim, C. H. Lee, M. R. Lee and J. H. Kim, “Multivariate Analysis of the Survival Rate for Treatment Modalities in Incurable Stage IV Colorectal Cancer,” Journal of the Korean Society of Coloproctology, Vol. 28, No. 1, 2012, pp. 35-41. doi:10.3393/jksc.2012.28.1.35
[12] H. Rosen, G. V. Kornek, et al., “Randomized Comparison of Combination Chemotherapy plus Supportive Care with Supportive Care Alone in Patients with Metastatic Colorectal Cancer,” BMJ, Vol. 306, No. 6880, 1993, pp. 752-755. doi:10.1136/bmj.306.6880.752
[13] P. M. Hoff, R. Ansari, G. Batist, et al., “Comparison of Oral Capecitabine versus Intravenous Fluorouracil plus Leucovorin as First-Line Treatment in 605 Patients with Metastatic Colorectal Cancer: Results of a Randomized Phase III Study,” Journal of Clinical Oncology, Vol. 19, No. 8, 2001, pp. 2282-2292.
[14] P. C. Simmonds, “Palliative Chemotherapy for Advanced Colorectal Cancer: Systematic Review and Meta-Analysis,” Colorectal Cancer Collaborative Group, Vol. 321, No. 7260, 2000, pp. 531-535.
[15] J. Y. Douillard, D. Cunningham, A. D. Roth, et al., “Irinotecan Combined with Fluorouracil Compared with Fluorouracil Alone as First-Line Treatment for Metastatic Colorectal Cancer: A Multicentre Randomised Trial,” Lancet, Vol. 355, No. 9209, 2000, pp. 1041-1047. doi:10.1016/S0140-6736(00)02034-1
[16] C. H. Kohne, E. van Cutsem, J. Wils, et al., “Phase III Study of Weekly High-Dose Infusional Fluorouracil plus Folinic Acid with or without Irinotecan in Patients with Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986,” Journal of Clinical Oncology, Vol. 23, No. 22, 2005, pp. 4856-4865. doi:10.1200/JCO.2005.05.546
[17] S. Giacchetti, B. Perpoint, R. Zidani, et al., “Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil-Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 18, No. 1, 2000, pp. 136-147.
[18] C. Tournigand, T. André, E. Achille, et al., “FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study,” Journal of Clinical Oncology, Vol. 22, No. 2, 2004, pp. 229-237. doi:10.1200/JCO.2004.05.113
[19] G. Colucci, V. Gebbia, G. Paoletti, F. Giuliani, et al., “Phase III Randomized Trial of FOLFIRI versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale,” Journal of Clinical Oncology, Vol. 23, No. 22, 2005, pp. 4866-4875. doi:10.1200/JCO.2005.07.113
[20] J. Feliu, A. Salud, P. Escudero, et al., “XELOX (Capecitabine plus Oxaliplatin) as First-Line Treatment for Elderly Patients over 70 Years of Age with Advanced Colorectal Cancer,” British Journal of Cancer, Vol. 94, No. 7, 2006, pp. 969-975. doi:10.1038/sj.bjc.6603047
[21] G. Masi, E. Vasile, F. Loupakis, et al., “Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis,” Journal of the National Cancer Institute, Vol. 103, No. 1, 2011, p. 21. doi:10.1093/jnci/djq456
[22] H. Hurwitz, L. Fehrenbacher, W. Novotny, et al., “Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer,” New England Journal of Medicine, Vol. 350, No. 23, 2004, pp. 2335-2342. doi:10.1056/NEJMoa032691
[23] C. S. Fuchs, J. Marshall and J. Barrueco, “Randomized, Controlled Trial of Irinotecan plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Updated Results from the BICC-C Study,” Journal of Clinical Oncology, Vol. 26, No. 4, 2008, pp. 689-690. doi:10.1200/JCO.2007.15.5390
[24] D. Cunningham, Y. Humblet, S. Siena, et al., “Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer,” New England Journal of Medicine, Vol. 351, No. 4, 2004, pp. 337-345. doi:10.1056/NEJMoa033025
[25] D. J. Jonker, C. J. O’Callaghan, C. S. Karapetis, et al., “Cetuximab for the Treatment of Colorectal Cancer,” New England Journal of Medicine, Vol. 357, No. 20, 2007, pp. 2040-2048. doi:10.1056/NEJMoa071834
[26] E. Van Cutsem, C. H. Kohne, E. Hitre, J. Zaluski, et al., “Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer,” New England Journal of Medicine, Vol. 360, No. 14, 2009, pp. 1408-1417. doi:10.1056/NEJMoa0805019
[27] E. Van Cutsem, M. Peeters, S. Siena, et al., “Open-Label Phase III Trial of Panitumumab plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 25, No. 13, 2007, pp. 1658-1664. doi:10.1200/JCO.2006.08.1620
[28] J. Y. Douillard, S. Siena, J. Cassidy, et al., “Randomized, Phase III Trial of Panitumumab with Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) versus FOLFOX4 Alone as First-Line Treatment in Patients with Previously Untreated Metastatic Colorectal Cancer: The PRIME Study,” Journal of Clinical Oncology, Vol. 28, No. 31, 2010, pp. 4697-4705. doi:10.1200/JCO.2009.27.4860
[29] E. Van Cutsem, J. Tabernero, R. Lakomy, et al., “Intravenous Aflibercept versus Placebo in Combination with Irinotecan/5-FU (FOLFIRI) for Second-Line Treatment of Metastatic Colorectal Cancer (ADVANCED CC): Results of a Multinational Phase III Trial (EFC10262-VELOUR) (ESMO Abstract O-0024),” Annals of Oncology, Vol. 22, Suppl. 5, 2011, p. v8
[30] E. Van Cutsem, A. F. Sobrero, S. Siena, et al., “Phase III CORRECT Trial of Regorafenib in Metastatic Colorectal Cancer (Advanced CC),” Journal of Clinical Oncology, Vol. 30., 2012, Abstract 3502.
[31] W. T. C. Chua, W. Liauw, F. Chu and D. L. Morris, “Viewing Metastatic Colorectal Cancer as a Curable Chronic Disease,” American Journal of Clinical Oncology, Vol. 34, 2012, pp. 77-80. doi:10.1097/COC.0b013e3181fe4444
[32] N. Petrelli, H. O. Douglass Jr., L. Herrera, et al., “The Modulation of Fluorouracil with Leucovorin in Metastatic Colorectal Carcinoma: A Prospective Randomized Phase III trial. Gastrointestinal Tumor Study Group,” Journal of Clinical Oncology, Vol. 7, No. 10, 1989, pp. 1419-1426.
[33] R. M. Goldberg, D. J. Sargent, R. F. Morton, et al., “A Randomized Controlled Trial of Fluorouracil plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients with Previously Untreated Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 22, No. 1, 2004, pp. 23-30. doi:10.1200/JCO.2004.09.046
[34] M. A. Poon, M. J. O’Connell, C. G. Moertel, et al., “Biochemical Modulation of Fluorouracil: Evidence of Significant Improvement of Survival and Quality of Life in Patients with Advanced Colorectal Carcinoma,” Journal of Clinical Oncology, Vol. 7, No. 10, 1989, pp. 1407-1418.
[35] N. Petrelli, L. Herrera, Y. Rustum, et al., “A prospective Randomized Trial of 5-Fluorouracil versus 5-Fluorouracil and High-Dose Leucovorin versus 5-Fluorouracil and Methotrexate in Previously Untreated Patients with Advanced Colorectal Carcinoma,” Journal of Clinical Oncology, Vol. 5, No. 10, 1987, pp. 1559-1565.
[36] A. de Gramont, J. F. Bosset, C. Milan, et al., “Randomized Trial Comparing Monthly Low-Dose Leucovorin and Fluorouracil Bolus with Bimonthly High-Dose Leucovorin and Fluorouracil Bolus plus Continuous Infusion for Advanced Colorectal Cancer: A French Intergroup Study,” Journal of Clinical Oncology, Vol. 15, No. 2, 1997, pp. 808-815.
[37] P. M. Hoff, R. Ansari, G. Batist, et al., “Comparison of Oral Capecitabine versus Intravenous Fluorouracil plus Leucovorin as First-Line Treatment in 605 Patients with Metastatic Colorectal Cancer: Results of a Randomized Phase III Study,” Journal of Clinical Oncology, Vol. 19, No. 8, 2001, pp. 2282-2292.
[38] E. Van Cutsem, C. Twelves, J. Cassidy, et al., “Oral Capecitabine Compared with Intravenous Fluorouracil plus Leucovorin in Patients with Metastatic Colorectal Cancer: Results of a Large Phase III Study,” Journal of Clinical Oncology, Vol. 19, No. 21, 2001, pp. 4097-4106.
[39] D. Cunningham, S. Pyrhonen, R. D. James, et al., “Randomized Trial of Irinotecan plus Supportive Care versus Supportive Care Alone after Fluorouracil Failure for Patients with Metastatic Colorectal Cancer,” Lancet, Vol. 352, 1998, pp. 1413-1416. doi:10.1016/S0140-6736(98)02309-5
[40] J. Y. Douillard, D. Cunningham, A. D. Roth, et al., “Irinotecan Combined with Fluorouracil Compared with Fluorouracil Alone as First-Line Treatment for Metastatic Colorectal Cancer: A Multicenter Randomized Trial,” Lancet, Vol. 355, No. 9209, 2000, pp. 1041-0147. doi:10.1016/S0140-6736(00)02034-1
[41] L. B. Saltz, J. V. Cox, C. Blanke, et al., “Irinotecan plus Fluorouracil and leucovorin for Metastatic Colorectal Cancer. Irinotecan Study Group,” New England Journal of Medicine, Vol. 343, No. 13, 2000, pp. 905-914. doi:10.1056/NEJM200009283431302
[42] M. L. Rothenberg, A. M. Oza, R. H. Bigelow, et al., “Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared with either Therapy Alone in Patients with Progressive Colorectal Cancer after Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial,” Journal of Clinical Oncology, Vol. 21, No. 11, 2003, pp. 2059-2069. doi:10.1200/JCO.2003.11.126
[43] A. de Gramont, A. Figer, M. Seymour, et al., “Leucovorin and Fluorouracil with or without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer,” Journal of Clinical Oncology, Vol. 18, No. 16, 2000, pp. 2938-2947.
[44] A. Grothey, B. Deschler, H. Kroening, et al., “Phase III Study of Bolus 5-Fluorouracil (5-FU)/Folinic Acid (FA) (Mayo) vs Weekly High-Dose 24h 5-FU Infusion/FA + Oxaliplatin in Advanced Colorectal Cancer (Abstract)” Proceedings of American Society of Clinical Oncology, Vol. 21, 2002, p. 129a.
[45] J. Cassidy, J. Tabernero, C. Twelves, et al., “XELOX (Capecitabine plus Oxaliplatin): Active First-Line Therapy for Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 22, No. 11, 2004, pp. 2084-2091. doi:10.1200/JCO.2004.11.069
[46] H. T. Arkenau, D. Arnold, J. Cassidy, et al., “Efficacy of Oxaliplatin plus Capecitabine or Infusional Fluorouracil/ Leucovorin in Patients with Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials,” Journal of Clinical Oncology, Vol. 26, 2008, p. 5910. doi:10.1200/JCO.2008.16.7759
[47] H. K. Sanoff, D. J. Sargent, M. E. Campbell, et al., “Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741” J Clin Oncol, Vol. 26, 2008, pp. 5721. doi:10.1200/JCO.2008.17.7147
[48] A. Falcone, S. Ricci, I. Brunetti, et al., “Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared with Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest,” Journal of Clinical Oncology, Vol. 25, No. 13, 2007, pp. 1670-1676. doi:10.1200/JCO.2006.09.0928
[49] J. Souglakos, N. Androulakis, K. Syrigos, et al., “FOLFOXIRI (Folinic Acid, 5-Fluorouracil, Oxaliplatin and Irinotecan) vs FOLFIRI (Folinic Acid, 5-Fluorouracil and Irinotecan) as First-Line Treatment in Metastatic Colorectal Cancer (ADVANCED CC): A Multicenter Randomized Phase III Trial from the Hellenic Oncology Research Group (HORG),” British Journal of Cancer, Vol. 94, 2006, p. 798. doi:10.1038/sj.bjc.6603011
[50] R. M. Goldberg, M. L. Rothenberg, E. Van Cutsem, et al., “The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer,” Oncologist, Vol. 12, No. 1, 2007, pp. 38-50. doi:10.1634/theoncologist.12-1-38
[51] M. T. Seymour, T. S. Maughan, J. A. Ledermann, et al., “Different Strategies of Sequential and Combination Chemotherapy for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS): A Randomized Controlled Trial,” Lancet, Vol. 370, 2007, pp. 143-152. doi:10.1016/S0140-6736(07)61087-3
[52] M. Koopman, N. F. Antonini, J. Douma, et al., “Sequential versus Combination Chemotherapy with Capecitabine, Irinotecan, and Oxaliplatin in Advanced Colorectal Cancer (CAIRO): A Phase III Randomized Controlled Trial,” Lancet, Vol. 370, 2007, pp. 135-142. doi:10.1016/S0140-6736(07)61086-1
[53] C. Tournigand, A. Cervantes, A. Figer, et al., “OPTIMOX1: A Randomized Study of FOLFOX4 or FOL-FOX7 with Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study,” Journal of Clinical Oncology, Vol. 24, 2006, pp. 394-400. doi:10.1200/JCO.2005.03.0106
[54] B. Chibaudel, F. Maindrault-Goebel, G. Lledo, et al., “Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Studym” Journal of Clinical Oncology, Vol. 27, 2009, pp. 5727-5733. doi:10.1200/JCO.2009.23.4344
[55] R. A. Adams, A. M. Meade, M. T. Seymour, et al., “Intermittent versus Continuous Oxaliplatin and Fluoropyrimidine Combination Chemotherapy for First-Line Treatment of Advanced Colorectal Cancer: Results of the Randomized Phase 3 MRC COIN Trial,” Lancet Oncology, Vol. 12, 2011, pp. 642-653. doi:10.1016/S1470-2045(11)70102-4
[56] L. T. Macedo, A. B. da Costa Lima and A. D. Sasse, “Addition of Bevacizumab to First-Line Chemotherapy in Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis, with Emphasis on Chemotherapy Subgroups,” BMC Cancer, Vol. 12, No. 1, 2012, p. 89. doi:10.1186/1471-2407-12-89
[57] F. Kabbinavar, H. I. Hurwitz, L. Fehrenbacher, et al., “Phase II, Randomized Trial Comparing Bevacizumab plus Fluorouracil (FU)/Leucovorin (LV) with FU/LV Alone in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 21, No. 1, 2003, pp. 60-65. doi:10.1200/JCO.2003.10.066
[58] L. B. Saltz, S. Clarke, E. Díaz-Rubio, et al., “Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study,” Journal of Clinical Oncology, Vol. 26, No. 12, 2008, pp. 2013-2019. doi:10.1200/JCO.2007.14.9930
[59] D. Arnold, T. Andre, J. Bennouna, et al., “Bevacizumab (BEV) plus Chemotherapy (CT) Continued Beyond First Progression in Patients with Metastatic Colorectal Cancer (Advanced CC) Previously Treated with BEV plus CT: Results of a Randomized Phase III Intergroup Study (TML Study),” Journal of Clinical Oncolog, Vol. 30, 2012, Abstract CRA3503.
[60] C. S. Karapetis, S. Khambata-Ford, D. J. Jonker, et al., “K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer,” New England Journal of Medicine, Vol. 359, No. 17, 2008, pp. 1757-1765. doi:10.1056/NEJMoa0804385
[61] R. G. Amado, M. Wolf, M. Peeters, et al., “Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncolog, Vol. 26, No. 10, 2008, pp. 1626-1634. doi:10.1200/JCO.2007.14.7116
[62] T. S. Maughan, R. Adams, C. G. Smith, et al., “Identification of Potentially Responsive Subsets When Cetuximab Is Added to Oxaliplatin-Fluoropyrimidine Chemotherapy in First-Line Advanced Colorectal Cancer (aCC): Mature Results of the MRC COIN Trial (Abstract 3502)” Journal of Clinical Oncolog, Vol. 28, 2010, p. 261s.
[63] National Cancer Institute, “Phase III Randomized Study of Cetuximab and/or Bevacizumab in Combination with either Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX) or Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients with Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum,” 2012. http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=5463125
[64] A. F. Sobrero, J. Maurel, L. Fehrenbacher, et al., “EPIC: Phase III Trial of Cetuximab plus Irinotecan after Fluoropyrimidine and Oxaliplatin Failure in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncolog, Vol. 26, No. 14, 2008, pp. 2311-2319. doi:10.1200/JCO.2007.13.1193
[65] M. Peeters, T. J. Price, A. Cervantes, et al., “Randomized Phase III Study of Panitumumab with Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared with FOLFIRI Alone as Second-Line Treatment in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncolog, Vol. 28, No. 3, 2010, pp. 4706-4713. doi:10.1200/JCO.2009.27.6055
[66] J. Tol, M. Koopman, A. Cats, et al., “Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer,” New England Journal of Medicine, Vol. 360, 2009, pp. 563-572. doi:10.1056/NEJMoa0808268
[67] J. R. Hecht, E. Mitchell, T. Chidiac, et al., “A randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared with Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer,” Journal of Clinical Oncolog, Vol. 27, No. 5, 2009, pp. 672-680. doi:10.1200/JCO.2008.19.8135
[68] B. Nordlinger, H. Sorbye, B. Glimelius, et al., “Perioperative Chemotherapy with FOLFOX4 and Surgery versus Surgery Alone for Resectable Liver Metastases from Colorectal Cancer (EORTC Intergroup Trial 40983): A Randomized Controlled Trial,” Lancet, Vol. 371, No. 9617, 2008, pp. 1007-1016. doi:10.1016/S0140-6736(08)60455-9
[69] E. Mitry, A. L. Fields and H. Bleiberg, “Adjuvant Chemotherapy after Potentially Curative Resection of Metastases from Colorectal Cancer: A Pooled Analysis of Two Randomized Trials,” Journal of Clinical Oncolog, Vol. 26, No. 30, 2008, pp. 4906-4911. doi:10.1200/JCO.2008.17.3781
[70] R. Adam, D. A. Wicherts, R. J. de Haas, et al., “Patients with Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?” Journal of Clinical Oncolog, Vol. 27, No. 11, 2009, pp. 1829-1835. doi:10.1200/JCO.2008.19.9273
[71] T. Delaunoit, S. R. Alberts, D. J. Sargent, et al., “Chemotherapy Permits Resection of Metastatic Colorectal Cancer: Experience from Intergroup N9741,” Annals of Oncology, Vol. 16, No. 3, 2005, pp. 425-429. doi:10.1093/annonc/mdi092
[72] C. Barone, G. Nuzzo, A. Cassano, et al., “Final Analysis of Colorectal Cancer Patients Treated with Irinotecan and 5-Fluorouracil plus Folinic Acid Neoadjuvant Chemotherapy for Unresectable Liver Metastases,” British Journal of Cancer, Vol. 97, 2007, pp. 1035-1039. doi:10.1038/sj.bjc.6603988
[73] Z. Zhao, E. Pelletier, B. Barber, et al., “Major Surgery in Patients with Metastatic Colorectal Cancer in Western Europe,” Journal of Gastrointestinal Cancer, Vol. 43, No. 3, 2012, pp. 456-461. doi:10.1007/s12029-011-9349-y
[74] T. C. Chua and D. L. Morris, “Therapeutic Potential of Surgery for Metastatic Colorectal Cancer,” Scandinavian Journal of Gastroenterology, Vol. 47, No. 3, 2012, pp. 258-268. doi:10.3109/00365521.2012.640823
[75] N. Brunner and H. J. Nielsen, “Directions for Further Improvements of Treatment of Metastatic Colorectal Cancer,” Scandinavian Journal of Gastroenterology, Vol. 47, No. 3, 2012, pp. 363-364. doi:10.3109/00365521.2012.640837
[76] J. L. Marshall, “Managing Potentially Resectable Metastatic Colon Cancer,” Gastrointestinal Cancer Research, Vol. 2, Suppl. 2, 2008, pp. S23-S26.
[77] K. Okuno, “Surgical Treatment for Digestive Cancer,” Digestive Surgery, Vol. 24, No. 2, 2007, pp. 108-114. doi:10.1159/000101897
[78] G. Brandi, J. Corbelli and F. de Rosa, “Second Surgery or Chemotherapy for Relapse after Radical Resection of Colorectal Cancer Metastases,” Langenbeck’s Archives of Surgery, Vol. 397, No. 7, 2012, pp. 1069-1077. doi:10.1007/s00423-012-0974-0
[79] R. Adam, V. Delvart, G. Pascal, et al., “Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy. A Model to Predict Long-Term Survival,” Annals of Surgery, Vol. 240, 2004, pp. 644-658.
[80] D. Clements, P. D. Rao, D. Ramanathan, et al., “Management of the Asymptomatic Primary in the Palliative Treatment of Metastatic Colorectal Cancer,” Colorectal Disease, Vol. 11, No. 8, 2009, pp. 845-848. doi:10.1111/j.1463-1318.2008.01695.x
[81] A. P. Stillwell, P. G. Buettner and Y. H. Ho, “Meta-Analysis of Survival of Patients with Stage IV Colorectal Cancer Managed with Surgical Resection versus Chemotherapy Alone,” World Journal of Surgery, Vol. B4, 2010, pp. 797-807. doi:10.1007/s00268-009-0366-y
[82] S. Stelzner, G. Hellmich, R. Koch and K. Ludwig, “Factors Predicting Survival in Stage IV Colorectal Carcinoma Patients after Palliative Treatment: A Multivariate Analysis,” Journal of Surgical Oncology, Vol. 89, No. 4, 2005, pp. 211-217. doi:10.1002/jso.20196
[83] M. G. W. Scheer, C. E. J. Sloots, G. J. van der Wilt and T. J. M. Ruers, “Management of Patients with Asymptomatic Cancer and Synchronous Irresectable Metastases,” Annals of Oncology, Vol. 19, No. 11, 2008, pp. 1829-1835. doi:10.1093/annonc/mdn398
[84] S. Ahmed, R. K. Shahid, A. Leis, et al., “Should Palliative Resection of Primary Tumor Be Performed in Patients with Advanced Colorectal Cancer? A Systematic Review and Meta-Analysis” Annals of Oncology, Vol. 23, Suppl. 9, 2012, Abs531.
[85] E. A. Bonin and T. H. Baron, “Update on the Indications and Use of Colonic Stents,” Current Gastroenterology Reports, Vol. 12, No. 5, 2010, pp. 374-382. doi:10.1007/s11894-010-0136-x
[86] K. M. Dalal, M. J. Gollub, T. J. Miner, et al., “Temple, Management of Patients with Malignant Bowel Obstruction and Stage IV Colorectal Cancer,” Journal of Palliative Medicine, Vol. 14, No. 7, 2011, pp. 822-928. doi:10.1089/jpm.2010.0506
[87] H. Chouhan, C. X. Wong, P. Maharaj, M. J. Lawrence, A. Hunter and J. W. Moore, “Colorectal Stenting for Malignant Obstruction: An 8-Year Clinical Experience,” ANZ Journal of Surgery, Vol. 82, No. 6, 2012, pp. 408-411. doi:10.1111/j.1445-2197.2012.06086.x
[88] M. Karoui, A. Charachon, C. Delbaldo, et al., “Stents for Palliation of Obstructive Metastatic Colon Cancer,” Archives of Surgery, Vol. 142, No. 7, 2007, pp. 619-623. doi:10.1001/archsurg.142.7.619
[89] S. Meisner, F. Gonzalez-Huix, J. G. Vandervoort, A. Repici, et al., “Self-Expanding Metal Stenting for Palliation of Patients with Malignant Colonic Obstruction: Effectiveness and Efficacy on 225 Patients with 12-Month’s Follow-Up,” Gastroenterology Research and Practice, Vol. 2012, 2012, pp. 296-347. doi:10.1155/2012/296347
[90] D. Williams, R. Law and A. M. Pullyblank, “Colorectal Stenting in Malignant Large Bowel Obstruction: The Learning Curve,” International Journal of Surgical Oncology, 2011, Article ID: 917848.
[91] W. S. Lee, J. H. Baek, J. M. Kang, et al., “The Outcome after Stent Placement or Surgery as the Initial Treatment for Obstructive Primary Tumor in Patients with Stage IV Colon Cancer,” The American Journal of Surgery, Vol. 203, No. 6, 2012, pp. 715-719. doi:10.1016/j.amjsurg.2011.05.015
[92] A. Lamazza, E. Fiori, A. Schillaci, et al., “Self-Expandable Metallic Stents in Patients with Stage IV Obstructing Colorectal Cancer,” World Journal of Surgery, Vol. 36, No. 12, 2012, pp. 2931-2936. doi:10.1007/s00268-012-1767-x
[93] E. Angenete, D. Asplund, M. Bergstrom and P. O. Park, “Stenting for Colorectal Cancer Obstruction Compared to Surgery—A Study of Consecutive Patients in a Single Institution” International Journal of Colorectal Disease, Vol. 27, No. 5, 2012, pp. 665-670. doi:10.1007/s00384-011-1374-6
[94] H. J. Lee, S. P. Hong, J. H. Cheon, T. I. Kim, B. S. Min, N. K. Kim and W. H. Kim, “Long-Term Outcome of Palliative Therapy for Malignant Colorectal Obstruction with Unresectable Metastatic Colorectal Cancers: Endoscopic Stenting versus Surgery,” Gastrointestinal Endoscopy, Vol. 73, No. 3, 2011, pp. 535-543. doi:10.1016/j.gie.2010.10.052
[95] M. Mates, D. Dudgeon, L. C. Hookey, et al., “Intractable Nausea in a Patient with Metastatic Colorectal Cancer Following Insertion of a Colonic Stent,” Journal of Pain and Symptom Management, Vol. 36, No. 1, 2008, pp. e6-e10. doi:10.1016/j.jpainsymman.2008.02.003
[96] N. Mahmound and K. B. Dunn, “Metastasectomy for Stage IV Colorectal Cancer,” Diseases of the Colon & Rectum, Vol. 53, No. 7, 2010, pp. 1080-1092. doi:10.1007/DCR.0b013e3181dcadbc
[97] A. R. Knudsen, A. S. Kannerup, F. V. Mortensen and D. T. Nielsen, “Radiofrequency Ablation of Colorectal Metastases Downstaged by Chemotherapy,” ACTA Radiology, Vol. 50, No. 7, 2009, pp. 716-721. doi:10.1080/02841850902991634
[98] M. F. Mulcahy, R. J. Lewandowski, S. M. Ibrahim, et al., “Radioembolization of Colorectal Hepatic Metastases Using Yttrium-90 Micropheres,” Cancer, Vol. 115, 2009, pp. 1849-1858. doi:10.1002/cncr.24224

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.